

Index

- Acceptance and Commitment Therapy (ACT)
 cross-cultural issues, 71
 future research, 233
 as novel treatment model, 180
 Parkinson's disease, late-life anxiety and, 148
- Acculturation, late-life anxiety and, 14
- Activity, Balance, Learning and Exposure (ABLE)
 treatment, fear of falling and, 178
- Adjusting to Chronic Conditions Using Education, Support, and Skills (ACCESS), 179–180
- Adverse effects of pharmacological treatment, 193–194
- Agoraphobia
 clinical assessment of late-life anxiety and, 86–87
 DSM-5 and, 87
- Agoraphobic Cognitions Questionnaire (ACQ), 87
- Alcohol use disorder
 co-morbidity of anxiety and, 4
 subthreshold late-life anxiety and, 46
- Alcohol Use Disorder and Associated Disabilities Interview (AUDADIS), 11, 13
- Alerting, 98
- Almeida, O. P., 15–16
- Alpidem, 198
- Alprazolam, 198
- Alzheimer's disease
 amyloid-beta deposition and, 125
 apolipoprotein E ϵ 4 and, 123
 cardiovascular disease (CVD) and, 125
 cognitive behavioural therapy (CBT) and, 52
 cognitive functioning and, 117
 genetic factors in, 123
 neuropsychiatric anxiety and, 120–121
- American College of Sports Medicine, 72
- American Heart Association, 72
- American Journal of Geriatric Psychiatry*, 226
- American Psychiatric Association. *See* Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
- American Society of Clinical Oncology (ASCO), 167
- Ames, D., 11
- Amputation, subacute settings and late-life anxiety, 158
- Amygdala
 anxiety and, 1, 205
 attention bias and, 109–110
 blastolateral group (BLA), 207
 centromedial group (CeA), 207, 208
 cognitive functioning and, 123
 mediation of fear learning and extinction in, 209–210
 neuromodulation of fear and anxiety circuits, 211
 neurons in, 207–208
 Parkinson's disease, late-life anxiety and, 145
 Pavlovian fear conditioning and, 206
 physiology of, 207–208
- Amyloid-beta deposition, Alzheimer's disease and, 125
- Andreas, S., 12
- Animal models of fear and anxiety
 amygdala, mediation of fear learning and extinction in, 209–210
 anxiety compared, 206
 cognitive behavioural therapy (CBT), fear conditioning and extinction and, 214
 defined, 205
 gamma-aminobutyric acid (GABA) system, fear conditioning and extinction and, 213–214
 hippocampus, mediation of fear learning and extinction in, 210–211
 neuromodulation of fear and anxiety circuits, 211–212
 overview, 7, 205–206, 214–218
 Pavlovian fear conditioning, 206–207
 prefrontal cortex, mediation of fear learning and extinction in, 210–211
- Anterior cingulate
 anxiety and, 1
 attention and, 97–98
 Parkinson's disease, late-life anxiety and, 145
- Anticonvulsants
 future research, 231
 overview, 200
 pregabalin, 200, 231
 treatment of late-life anxiety with, 200
- Antidepressants. *See also specific drug*
 buspirone, 200
 future research, 231
 generalized anxiety disorder (GAD) and, 174
 hyponatraemia and, 196
 monoamine oxidase inhibitors (MAOIs), 196
 overview, 195–196
 selective serotonin reuptake inhibitors (SSRIs), 146, 196

- Antidepressants (cont.)
 serotonin and noradrenaline (norepinephrine) reuptake inhibitors (SNRIs), 196
 suicide and, 196
 tricyclic antidepressants (TCAs), 72, 196
- Antipsychotics
 overview, 199
 quetiapine, 199, 231
 treatment of late-life anxiety with, 199
- Anxiety and Related Disorders Interview Schedule-5 (ADIS-5), 81
- Anxiety disorders not otherwise specified (ADNOS)
 Parkinson's disease and, 140, 141–142
 subthreshold late-life anxiety and, 33, 51–52
- Anxiety in Cognitive Impairment and Dementia (ACID), 87–88
- Anxiety Sensitivity Index (ASI), 87
- Anxiety Status Inventory (ASI), Parkinson's disease and late-life anxiety and, 142
- Apolipoprotein E $\epsilon 4$, 123–124
- Ashwagandha, 201, 232
- Asnaani, A., 14
- Åström, M., 157
- Attention bias, depression and late-life anxiety and age difference, effect of, 107
 alerting and, 98
 amygdala and, 109–110
 anterior cingulate and, 97–98
 anxiety and, 101–108
 attention bias modification (ABM) training, 111
 bottom-up process in attention, 97–98
 co-morbidity of late-life anxiety and depression and, 109, 110
 depression and, 108–109
 empirical evidence of, 101–106
 executive function and, 98
 fear of falling and, 107–108
 four-stage process, 99
 functional connectivity in default mode network (DMN) and, 110
 functional magnetic resonance imaging (fMRI) and, 107, 110
 future research, 111–112
 generalized anxiety disorder (GAD) and, 107, 111
 integrated model, 110
 meditation and, 111
 neurophysiology of, 109–110
 neuropsychology of, 109–110
 orientating and, 98
 overview, 97
 pharmacological treatment, 110–111
 positivity effect and, 100
 prefrontal cortex and, 107, 109–110
 psychosocial treatment, 110–111
 research findings, 101–106
 state anxiety and, 101
 threat and, 99, 109, 111
 time and, 99
 top-down process in attention, 97–98
 trait anxiety and, 101–107
 worry and, 107
- Attention Control Theory (ACT)
 cognitive functioning and, 120
 depression and late-life anxiety and, 99
 subthreshold late-life anxiety and, 49
- Attention Process Training II (APT), executive dysfunction and, 178
- Australian National Survey of Mental Health, 4, 22
- Avoidant-vigilant response, 101
- Ayers, C. R., 129
- Bachelor-level lay providers (BLPs), 182
- Bar-Haim, Y., 99, 109, 110
- Basoudan, N., 228
- Baxter, A. J., 11, 66
- Beaudreau, Sherry A., 6, 118, 128
- Beck, A. T., 98–99
- Beck Anxiety Inventory (BAI)
 clinical assessment of late-life anxiety and, 83, 87
 diagnosis of late-life anxiety and, 24
 overview, 4
 Parkinson's disease and late-life anxiety and, 142, 147
- Behavioural observations, 88
- Benzodiazepines (BZDs)
 ceasing use of, 195
 cross-cultural issues, 72
 future research, 231
 gamma-aminobutyric acid (GABA) system and, 197, 213
 generalized anxiety disorder (GAD) and, 174
 Parkinson's disease, late-life anxiety and, 146
 subthreshold late-life anxiety and, 51
 treatment of late-life anxiety with, 197–198
 Z-drugs versus, 198
- Beta-blockers, 200–201
- Bower, Emily, 6, 85
- Braam, A. W., 44
- Bradley, B., 99, 109
- Brain-derived neurotrophic factor (BDNF)
 cognitive functioning and, 123–124
 Parkinson's disease, late-life anxiety and, 145
- Brenes, G. A., 235
- Breslau, J., 14
- Bryant, Christina, 5, 11, 25
- Buddhism, 71
- Burden of disease due to anxiety, 3, 11
- Burden of Disease Study, 11
- Bupirone
 antidepressants versus, 200
 sertraline versus, 196
 treatment of late-life anxiety with, 199–200
- Byers, A. L., 12
- Byrne, Gerard, 5, 6, 7
- BZD. *See* Benzodiazepines (BZDs)
- Calmer Life model, 180–181
- Campbell, G., 25
- Cannabidiol (CBD), 232
- Cannabis, 232

- Canuto, A., 12, 16
 Cardiovascular disease (CVD)
 Alzheimer's disease and, 125
 clinical assessment of late-life anxiety and, 90
 cognitive behavioural therapy (CBT) and, 52
 cognitive functioning and, 125
 subthreshold late-life anxiety, co-morbidity with, 50
 Care settings, late-life anxiety across
 home-based care (*See* Home-based care, late-life anxiety in)
 long-term care (*See* Long-term care, late-life anxiety in)
 overview, 6, 157
 palliative care settings (*See* Palliative care settings, late-life anxiety in)
 subacute settings (*See* Subacute settings, late-life anxiety in)
 Case formulation, 27
 CBT. *See* Cognitive behavioural therapy (CBT)
 Chamomile, 201, 232
 Childhood
 anxiety and, 2
 cognitive functioning and, 123
 Chou, K. L., 13, 15, 16
 Chronic obstructive pulmonary disease (COPD)
 clinical assessment of late-life anxiety and, 89
 cognitive behavioural therapy (CBT) and, 52
 in subacute settings, 158
 subthreshold late-life anxiety, co-morbidity with, 50
 Chronic pain, co-morbidity with subthreshold late-life anxiety, 51
 Citalopram, 196
 Clark, L. A., 98
 Clinical assessment of late-life anxiety
 agoraphobia and, 86–87
 Agoraphobic Cognitions Questionnaire (ACQ), 87
 Anxiety and Related Disorders Interview Schedule-5 (ADIS-5), 81
 Anxiety in Cognitive Impairment and Dementia (ACID), 87–88
 Anxiety Sensitivity Index (ASI), 87
 Beck Anxiety Inventory (BAI), 83, 87
 behavioural observations, 88
 cardiovascular disease (CVD) and, 90
 chronic obstructive pulmonary disease (COPD) and, 89
 cognitive functioning and, 126–128
 dementia and, 87–88
 diabetes and, 89–90
 diagnosis and, 79–80
 diversity differences in, 90
 ecological momentary assessment (EMA), 88–89
 experience and, 79–80
 fear of falling and, 85
 Fear of Falling Questionnaire (FFQ), 85
 Fear Survey Schedule-II (FSS-II), 85
 gender differences in, 90
 generalized anxiety disorder (GAD) and, 84
 Generalized Anxiety Disorder Severity Scale (GADSS), 82
 Geriatric Anxiety Inventory (GAI), 83
 Geriatric Anxiety Scale (GAS), 83–84
 Hamilton Anxiety Rating Scale (HAM-A), 82
 in home-based care, 161–162
 informant reports, 88
 information used in, 80
 Liebowitz Social Anxiety Scale (LSAS), 85–86
 in long-term care, 165
 Mini-International Neuropsychiatric Interview (MINI), 81–82
 Mobility Inventory (MI), 87
 Montreal Cognitive Assessment (MoCA), 128
 Older Adult Social Evaluative Scale (OASES), 86
 overview, 6, 79, 90–91
 in palliative care settings, 167
 panic disorder and, 86–87
 Panic Disorder Severity Scale, 82
 Parkinson's disease and, 89, 142–143
 Patient-Reported Outcomes Measurement Information System (PROMIS), 84
 Penn State Worry Questionnaire (PSWQ), 84–85
 pharmacological treatment, prior to, 193
 phobias and, 85
 physical illness and, 89–90
 physiological measures, 88
 presentation and, 79–80
 Rating Scale for Anxiety in Dementia (RAID), 87
 St. Louis University Mental Status (SLUMS) Examination, 128
 self-reports and, 82
 setting, relevance of, 80–81
 social anxiety disorder and, 85–86
 Social Interaction Anxiety Scale (SIAS), 86
 Social Phobia and Anxiety Inventory (SPAI), 86
 Social Phobia Scale (SPS), 86
 Structured Clinical Interview for DSM-5 Disorders (SCID), 81
 technology, use of, 88–89
Clinical Gerontologist, 226
 Clinical interviews, 24
 Cognitive behavioural therapy (CBT)
 Alzheimer's disease and, 52
 cardiovascular disease (CVD) and, 52
 chronic illness and, 179–180
 chronic obstructive pulmonary disease (COPD) and, 52
 cognitive functioning and, 129

- (CBT) (cont.)
 combination with
 pharmacological
 treatment, 174, 201
 cross-cultural issues, 71
 dementia and, 179
 executive dysfunction
 and, 178
 fear conditioning and
 extinction and, 214
 fear of falling and, 52, 178
 future research, 232–233
 generalized anxiety disorder
 (GAD) and, 6, 173
 hoarding disorder and, 177
 Internet-delivered cognitive
 behavioural therapy
 (iCBT), 182, 234–235
 meta-analytic evaluation of,
 173–174
 modular approaches, 180
 overview, 5, 6
 panic disorder and, 173
 Parkinson's disease
 and late-life anxiety and,
 52, 146–148, 174, 179
 pharmacological treatment
 versus, 201
 post-traumatic stress
 disorder (PTSD) and, 176
 sertraline versus, 196
 subthreshold late-life anxiety
 and, 51–53
 telephone-based treatment,
 181–182
 traditional efficacy trials,
 173–175
 younger populations
 compared, 174
- Cognitive bias. *See* Attention
 bias, depression and
 late-life anxiety and
- Cognitive Debt, 120
- Cognitive functioning, late-life
 anxiety and
 Alzheimer's disease and, 117
 amygdala and, 123
 apolipoprotein E ϵ 4 and,
 123–124
 Attention Control
 Theory, 120
 biological models generally,
 121, 126
 brain-derived neurotrophic
 factor (BDNF) and,
 123–124
- cardiovascular disease
 (CVD) and, 125
- childhood and, 123
- clinical assessment of late-
 life anxiety and, 126–128
- clinical implications
 generally, 126
- cognitive behavioural
 therapy (CBT) and, 129
- Cognitive Debt, 120
- complex cognitive
 abilities, 118
- cortisol and, 124
- depression and, 119
- early-life experience and, 123
- evolutionary basis for
 anxiety, 122
- gamma-aminobutyric acid
 (GABA) system and, 124
- generalized anxiety disorder
 (GAD) and, 117, 118–119
- genetic factors in anxiety,
 122–124
- hippocampus and, 123, 124
- hormones and, 124
- hyperthyroidism and, 125
- hypothalamic–pituitary–
 adrenal (HPA) axis
 and, 124
- hypothyroidism and, 125
- Mindfulness-based Stress
 Reduction (MBSR)
 and, 130
- Montreal Cognitive
 Assessment (MoCA), 128
- negative effects,
 118–119, 121
- neuropsychiatric anxiety,
 120–121
- neurotransmitters and, 124
- overview, 6, 117, 131
- Parkinson's disease and, 125
- pharmacological treatment
 and, 130
- prefrontal cortex and,
 123, 124
- problem-solving therapy
 (PST) and, 129–130
- Processing Efficiency
 Theory, 120
- St. Louis University Mental
 Status (SLUMS)
 Examination, 128
- sexual abuse and, 123–124
- specific cognitive
 abilities, 118
- studies of, 117–118
- thyroid disease and, 125
- treatment generally,
 128–129
- twin studies and, 122–123
- worry and, 119
- Cognitive impairment
 psychotropic drugs, use of in
 presence of, 194
- risk factor, anxiety as,
 227–228
- subthreshold late-life
 anxiety, co-morbidity
 with, 48–49
- symptom, anxiety as, 227
- Collaborative Psychiatric
 Epidemiology Survey
 (CPES), 14
- Community–academic
 partnership models, 182
- Co-morbidity of anxiety. *See*
also specific disease
 findings of studies, 16
- other conditions, 16
- overview, 3–4
- pharmacological treatment
 and, 191
- Complementary medicine, 201
- Composite International
 Diagnostic Interview
 (CID), 11, 13, 24, 27
- Confucianism, 67
- Contextual, Adult Lifespan
 Theory for Adapting
 Psychotherapy (CALTAP)
 model, 20, 24, 28–29
- Conti, E. C., 234
- Conventional treatment of
 anxiety, 4–5
- COPD. *See* Chronic obstructive
 pulmonary disease
 (COPD)
- Cortisol, cognitive functioning
 and, 124
- Coyne, J. C., 26
- Craddock, N., 21
- Creamer, M., 22
- Creighton, A. S., 13
- Cross-cultural issues in late-life
 anxiety
 Acceptance and
 Commitment Therapy
 (ACT) and, 71
 benzodiazepines (BZDs)
 and, 72
 Buddhism and, 71

- cognitive behavioural therapy (CBT) and, 71
 Confucianism and, 67
 cultural syndrome, 68
 culture defined, 63
 culture-specific disorders, 68
 death anxiety and, 70
 diagnosis and, 26–27, 68–69
 display rules and, 67
 epidemiology and, 13–14
 exercise and, 72
 family and, 71–72
 future research, 72–73
 Geriatric Anxiety Inventory (GAI) and, 69
 Hospital Anxiety and Depression Scale (HADS) and, 69
 immigration and, 69–70
 Mandala of Health and, 64–65
 mindfulness-based interventions and, 71
 non-Western cultures, 63
 overview, 5–6, 63, 72–73
 perception of mental disorders, 65–66
 pharmacological treatment and, 72
 presentation of symptoms and, 67–68
 prevalence of anxiety and, 66–67
 protective factors and, 69–70
 psychosocial treatment and, 70–72
 relaxation and, 71
 religious explanation for mental disorders, 65
 risk factors and, 69–70
 screening and, 68–69
 stigma and, 65–66
 supernatural explanation for mental disorders, 65
 Taoism and, 71
 tricyclic antidepressants (TCAs) and, 72
 Western cultures, 63
 Zen Buddhism and, 71
 Cuijpers, P., 235
 Cultural syndrome, 68
 Culture-specific disorders, 68
 CVD. *See* Cardiovascular disease (CVD)
- Daily functioning, effect of subthreshold late-life anxiety on, 45–46
 Darwin, Charles, 1, 205
 Davies, K. N., 25
 Davison, T. E., 13
 D-Cycloserine (DCS), 232
 Death anxiety, cross-cultural issues in late-life anxiety and, 70
 Decline of anxiety with age, 3
 Deep brain stimulation (DBS) treatment, 142
 Dementia
 clinical assessment of late-life anxiety and, 87–88
 cognitive behavioural therapy (CBT) and, 179
 co-morbidity with late-life anxiety, 16, 23
 long-term care, co-morbidity with late-life anxiety in, 164–165
 mindfulness-based interventions and, 179
 psychosocial treatment, 178–179
 risk factor, anxiety as, 227–228
 subthreshold late-life anxiety, co-morbidity with, 48–49
 symptom, anxiety as, 227
 Demeyer, I., 101
 Depression, Anxiety and Stress Scale (DASS-21), Parkinson's disease and late-life anxiety and, 147
 Depression, late-life anxiety and
 attention bias and (*See* Attention bias, depression and late-life anxiety and)
 Attention Control Theory (ACT) and, 99
 cognitive functioning and, 119
 cognitive theories and, 99–100
 findings of studies, 16
 information processing model and, 99
 maladaptive schemas and, 98–99
 mirtazapine and, 197
 nortriptyline and, 197
 overview, 4, 6
 socioemotional selectivity theory (SST) and, 100
 subthreshold late-life anxiety and, 47
 tripartite model of, 98
 De Raedt, R., 101
 Diabetes, clinical assessment of late-life anxiety and, 89–90
 Diagnosis of late-life anxiety
 age range as challenge of, 21
 Beck Anxiety Inventory (BAI), 24
 best practice in, 27–29
 CALTAP model, 20, 24, 28–29
 case formulation, 27
 challenges of, 21–24
 clinical assessment of late-life anxiety and, 79–80
 clinical interviews and, 24
 Composite International Diagnostic Interview (CIDI), 24, 27
 cross-cultural issues in, 26–27, 68–69
 dementia, co-morbidity with as challenge of, 23
 detection and recognition of symptoms as challenge of, 21–22
 differential presentation as challenge of, 22
 fear of falling as challenge of, 23
 future directions, 29
 generalized anxiety disorder (GAD), 29
 Geriatric Anxiety Inventory (GAI), 24–25
 Geriatric Depression Scale (GDS), 24
 GMS/AGECAT System, 25, 27
 Hamilton Anxiety Rating Scale (HAM-A), 24
 Hospital Anxiety and Depression Scale (HADS), 24–25, 26
 importance of, 20–21
 overview, 5, 20, 29
 physical illness, co-morbidity with as challenge of, 22–23

- Diagnosis (cont.)
 Rating Scale for Anxiety in Dementia (RAID), 24
 screening instruments, 24–26
 self-reports, problems with, 20–21
 shortcomings of existing diagnostic criteria, 3
 stigma as challenge of, 22
 Structured Clinical Interview for DSM-5 Disorders (SCID), 27
- Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
 agoraphobia and, 87
 anxiety defined, 205
 anxiety disorders not otherwise specified (ADNOS) and, 140
 changes to, 23–24
 clinical assessment of late-life anxiety and, 79
 cultural syndrome, 68
 hoarding disorder, 161–162
 late-life anxiety and, 20
 methodological issues, 10–11
 OCD and, 2, 23
 post-traumatic stress disorder (PTSD) and, 176
 PTSD and, 2, 23
 Structured Clinical Interview for DSM-5 Disorders (SCID), 81
 Western cultural bias in, 63
- Diagnostic Interview Schedule (DIS), 13
- Diefenbach, G. J., 68
- Diffusion tensor imaging (DTI), Parkinson's disease and late-life anxiety and, 145
- Dimensional measurement of anxiety, 2–3
- Disability-adjusted life-years (DALYs), 3
- Display rules, 67
- Dissanayaka, N., 6, 228, 233
- Diversity differences in clinical assessment of late-life anxiety, 90
- Dobkin, R. D., 147
- Dobzhansky, Theodosius, 218
- Donepezil, 200
- Dopamine dysregulation syndrome (DDS), 142
- Dopamine withdrawal syndrome (DWAS), 142
- Dreeben, Samuel, 6
- Driving anxiety, 230
- Drugs. *See* Pharmacological treatment of late-life anxiety
- DSM-5. *See* Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
- Duloxetine, 197
- Early-life experience
 anxiety and, 2
 cognitive functioning and, 123
 future research, 227
- Ecological momentary assessment (EMA), 88–89
- Edelstein, Barry, 6, 85, 88
- e-Health, 234–235
- Eldreth, D. A., 107
- enhanced community care (ECC), 181, 182
- Enquête sur la Santé des Aînés (ESA) Study, 13
- Epidemiology of late-life anxiety
 acculturation and, 14
 cultural differences and, 13–14
 findings of studies, 11
 methodological issues, 10–11
 nursing homes and, 13
 overview, 5, 10, 16
 population-based incidence estimates, 13
 population-based prevalence estimates, 12–13
- Escitalopram
 combination with cognitive behavioural therapy (CBT), 201
 treatment of late-life anxiety with, 196–197
- ESPRIT Study, 15
- Evolutionary basis for anxiety, 122
- Executive dysfunction
 Attention Process Training II (APT) and, 178
 cognitive behavioural therapy (CBT) and, 178
 psychosocial treatment of, 178
- Executive function, 98
- Exercise, cross-cultural issues, 72
- Eysenck, M. W., 120
- Family
 cross-cultural issues, 71–72
 palliative care and, 167
- Fan, A. Z., 90
- Fear and anxiety. *See* Animal models of fear and anxiety
- Fear of falling
 Activity, Balance, Learning and Exposure (ABLE) treatment and, 178
 attention bias and, 107–108
 clinical assessment of late-life anxiety and, 85
 cognitive behavioural therapy (CBT) and, 52, 178
 diagnosis of late-life anxiety, as challenge of, 23
 prevalence of, 177
 psychosocial treatment, 177–178
 subthreshold late-life anxiety and, 45
- Fear of Falling Questionnaire (FFQ), 85
- Fear Survey Schedule-II (FSS-II), 85
- Flint, A. J., 21
- Foulk, M. A., 233
- Fox, L. S., 101, 107
- Functional magnetic resonance imaging (fMRI)
 anxiety and, 1
 attention bias and, 107, 110
 future research, 227
 Parkinson's disease, late-life anxiety and, 145
- Future research
 Acceptance and Commitment Therapy (ACT), 233
 anticonvulsants, 231
 antidepressants, 231
 attention bias, 111–112
 benzodiazepines (BZDs), 231
 cannabidiol (CBD), 232

- cognitive behavioural therapy (CBT), 232–233
 conventional psychotropic medication, 231–232
 cross-cultural issues in late-life anxiety, 72–73
 early-life experience, 227
 e-Health, 234–235
 fMRI, 227
 genetic factors, 226–227
 incidence of late-life anxiety, 229–230
 late-life experience, 227
 mindfulness-based interventions, 233
 neural circuitry, 227
 novel agents, 232
 overview, 226, 235
 pharmacological treatment of late-life anxiety, 202, 230–231
 phytochemicals, 232
 prefrontal cortex, 227
 prevalence of late-life anxiety, 229–230
 psychosocial treatment of late-life anxiety, 182–183
 race, late-life anxiety and, 234
 risk factor, anxiety as, 227–229
 subthreshold late-life anxiety, 53–54
 symptom, anxiety as, 227
 telehealth, 234–235
 virtual reality (VR) technology, 234
- GAD. *See* generalized anxiety disorder (GAD)
 GAI. *See* Geriatric Anxiety Inventory (GAI)
 Galantamine, 200
 Galphimia, 201
 Gamma-aminobutyric acid (GABA) system
 benzodiazepines (BZDs) and, 197, 213
 cognitive functioning and, 124
 fear conditioning and extinction and, 213–214
 pharmacological treatment and, 189
 pregabalin and, 200
 Z-drugs and, 198
- Gatz, M., 226–227
 Gender differences in clinical assessment of late-life anxiety, 90
 Generalized anxiety disorder (GAD)
 alpidem and, 198
 alprazolam and, 198
 antidepressants and, 174
 attention bias and, 107, 111
 benzodiazepines (BZDs) and, 174
 clinical assessment of late-life anxiety and, 84
 cognitive behavioural therapy (CBT) and, 6, 173
 cognitive functioning and, 117, 118–119
 co-morbidity of, 4
 diagnosis of, 29
 duloxetine and, 197
 escitalopram and, 196–197
 ketazolam and, 198
 nortriptyline and, 197
 onset of, 4
 in palliative care settings, 166
 Parkinson's disease and, 139–140
 risk factors, 15
 subthreshold late-life anxiety and, 44, 46, 48
 telephone-based treatment, 181–182
 venlafaxine and, 197
 Generalized Anxiety Disorder Severity Scale (GADSS), 82
 Genetic factors
 in Alzheimer's disease, 123
 in anxiety, 1–2
 cognitive functioning and, 122–124
 future research, 226–227
 Parkinson's disease, late-life anxiety and, 145–146
 Geriatric Anxiety Inventory (GAI)
 clinical assessment of late-life anxiety and, 83
 cross-cultural issues, 69
 culturally specific responses, 229–230
 diagnosis of late-life anxiety and, 24–25
 long-term care and, 165
 overview, 4, 229
- Parkinson's disease, late-life anxiety and, 143
 pharmacological treatment, measurement of effect, 192
 Geriatric Anxiety Scale (GAS)
 clinical assessment of late-life anxiety and, 83–84
 long-term care and, 165
 overview, 4, 229
 pharmacological treatment, measurement of effect, 192
 Geriatric Depression Scale (GDS), 24
 Geriatric Resources for Assessment and Care of Elders (GRACE) model, 175
Ginkgo biloba, 201, 232
 GMS/AGECAT system, 11, 13, 14, 25, 27
 Gould, Christine, 6
 Grenier, Sébastien, 5, 50, 234
 Grigsby, A. B., 89–90
 Group psychodrama, Parkinson's disease and late-life anxiety and, 148
 Guy's/Age Concern Survey, 11
- HADS. *See* Hospital Anxiety and Depression Scale (HADS)
 Hall, J., 232–233
 Haller, J., 200
 Hamilton Anxiety Rating Scale (HAM-A)
 buspirone and, 200
 clinical assessment of late-life anxiety and, 82
 diagnosis of late-life anxiety and, 24
 duloxetine and, 197
 overview, 4
 oxazepam and, 198
 Parkinson's disease, late-life anxiety and, 142, 147
 pharmacological treatment, measurement of effect, 192
 pregabalin and, 200
 quetiapine and, 199
 sertraline and, 196
 Hantke, Nathan, 6
 Hatzdimitriadou, E., 66
 Headaches, co-morbidity with subthreshold late-life anxiety, 51

- Hearing impairment,
 co-morbidity with
 subthreshold late-life
 anxiety, 51
- Hendriks, G. J., 201
- Herbal medicines, 201
- Hinton, D. E., 13–14
- Hippocampus
 anxiety and, 1, 205
 cognitive functioning and,
 123, 124
 mediation of fear learning
 and extinction in,
 210–211
 neuromodulation of fear and
 anxiety circuits, 211
 Pavlovian fear conditioning
 and, 206
 physiology of, 208–209
- Hoarding disorder
 cognitive behavioural
 therapy (CBT) and, 177
 diagnostic features, 177
 home-based care and late-
 life anxiety and, 161–162
 prevalence of, 177
 psychosocial treatment, 177
- Hofmann, S. G., 13–14
- Home-based care, late-life
 anxiety in
 clinical assessment of late-
 life anxiety and, 161–162
 hoarding disorder in,
 161–162
 home-based primary care
 (HBPC) programmes, 160
 need for care, 160–161
 pharmacological treatment
 in, 164–165
 psychosocial treatment in,
 165, 182
 relaxation in, 162
 types of services,
 160–161
- home-based primary care
 (HBPC) programmes, 160
- Hopko, D. R., 85
- Hops, 201, 232
- Hormones, cognitive
 functioning and, 124
- Hospital Anxiety and
 Depression Scale (HADS)
 co-morbidity and, 16
 cross-cultural issues, 69
 diagnosis of late-life anxiety
 and, 24–25, 26
- Parkinson's disease, late-life
 anxiety and, 142, 147
 risk factors, 15–16
- Hosseini, Charissa, 5–6, 14
- Howard, R. J., 120
- Hwang, W. C., 71
- Hyperthyroidism, cognitive
 functioning and, 125
- Hyponatremia, antidepressants
 and, 196
- Hypothalamic–pituitary–
 adrenal (HPA) axis
 anxiety and, 1, 2
 cognitive functioning
 and, 124
- Hypothyroidism, cognitive
 functioning and, 125
- Immigration, cross-cultural
 issues, 69–70
- Improving Mood – Promoting
 Access to Collaborative
 Treatment (IMPACT)
 model, 175
- Impulse control disorders
 (ICDs), 142
- Incidence of late-life anxiety
 future research, 229–230
 population-based
 estimates, 13
- Informant reports, 88
- Information processing model,
 depression and late-life
 anxiety and, 99
- Institute of Medicine (IOM),
 175, 182
- Insula, anxiety and, 1
- International Classification of
 Diseases, 10th Revision
 (ICD-10)
 culture-specific disorders, 68
 methodological issues,
 10–11
 OCD and, 2
 PTSD and, 2
 Western cultural bias in, 63
- International
 Psychogeriatrics*, 226
- Internet-delivered cognitive
 behavioural therapy
 (iCBT), 182, 234–235
- Jackson, H., 11
- Jimenez, D. E., 66, 90
- Journal of Anxiety
 Disorders*, 226
- Kang, H.-J., 13, 15
- Karlsson, B., 22
- Kava, 201, 232
- Ketazolam, 198
- Kissane, D. W., 13
- Knight, B. G., 20, 27, 101, 107,
 108–109
- Kogan, J. N., 85, 88
- Kok, Brian, 6
- Kraepelien, M., 147
- Kreifelts, B., 227
- Kwangju Study, 13, 15
- Lee, K., 65, 66
- Lee, L. O., 101, 226–227
- Lemon balm, 201, 232
- Lenze, E. J., 130
- Letamendi, A. M., 67–68
- Li, S., 66
- Liebowitz Social Anxiety Scale
 (LSAS)
 clinical assessment of late-
 life anxiety and, 85–86
 Parkinson's disease, late-life
 anxiety and, 142
- Limbic system, anxiety and, 1
- Lin, Xiaoping, 5–6, 14
- Lithium, 200
- Longitudinal Aging Study
 Amsterdam, 11, 16
- Long-term care, late-life
 anxiety in
 characteristics of, 163
 clinical assessment of late-
 life anxiety and, 165
 continuum of care, 162–163
 dementia, co-morbidity
 with, 164–165
 Geriatric Anxiety Inventory
 (GAI) and, 165
 Geriatric Anxiety Scale
 (GAS) and, 165
 long-term care defined,
 162–163
 patient experience, 163
 pharmacological treatment,
 190, 194–195
 research findings, 164
- Ma, Vanessa, 6
- Mackenzie, C. S., 15
- MacLeod, C., 99
- Majercsik, E., 200
- Mandala of Health, 64–65
- Marchant, N. L., 120
- Marques, L., 67

- Massena, P. N., 69, 229–230
 Maters, G. A., 69
 Mathews, A., 99
 McBride, Shalagh, 6
 McKee, D. R., 88
 MDS-UPDRS – Anxiety Item,
 Parkinson's disease and
 late-life anxiety and, 142
 Medicare Skilled Home Care
 Program (US), 160
 Medication. *See*
 Pharmacological
 treatment of late-life
 anxiety
 Meditation, attention bias
 and, 111
 Memantine, 200
 MentDis_ICF65+ Study, 14, 16
 Menza, M., 145
 Mezhebovsky, I., 199
 Mindfulness-based Cognitive
 Therapy (MBCT), 233
 Mindfulness-based
 interventions
 cross-cultural issues, 71
 dementia and, 179
 future research, 233
 Parkinson's disease, late-life
 anxiety and, 148
 subthreshold late-life anxiety
 and, 52
 Mindfulness-based Stress
 Reduction (MBSR)
 cognitive functioning
 and, 130
 future research, 233
 as novel treatment
 model, 180
 Mini International
 Neuropsychiatric
 Interview (MINI), 11,
 81–82
 Mirtazapine, 197
 Mirza, S. S., 228
 Mobility Inventory (MI), 87
 Mogg, K., 99, 109
 Mohlman, J., 100, 107
 Monoamine oxidase inhibitors
 (MAOIs), 196
 Montreal Cognitive
 Assessment (MoCA), 128
 Mynors-Wallis, L., 21
 National Comorbidity Survey
 Replication (NCS-R), 12,
 14, 90
 National Guideline
 Clearinghouse (US),
 24–25
 National Institutes of Health
 (US), 84
 Nègre-Pagès, L., 49
 NESARC-II Study, 12–13,
 15, 16
 NESARC-III Study,
 3–4
 Neuropsychiatric anxiety,
 120–121
 Neuropsychiatric Inventory –
 Anxiety subscale
 (NPI-Anxiety)
 neuroticism and, 2
 Parkinson's disease, late-life
 anxiety and, 142
 Neuroticism, anxiety and, 2
 Neurotransmitters
 cognitive functioning
 and, 124
 Parkinson's disease, late-life
 anxiety and,
 144–145
 Nguyen, H., 111
 NMDA receptors, 214
 Noiret, N., 108
 Noradrenergic locus
 ceruleus, 145
 Nortriptyline, 197
 Novel agents, 232
 Nursing homes, prevalence
 estimates of late-life
 anxiety in, 13
 Obsessive-compulsive
 disorder (OCD)
 anxiety and, 2
 DSM-5 and, 23
 O'Hara, R., 118
 Okai, D., 147
 Older Adult Social Evaluative
 Scale (OASES), 86
 Omnibus Budget
 Reconciliation Act
 (US), 194
 Onset of anxiety, 4
 Orientating, 98
 Osteoporosis, co-morbidity
 with subthreshold late-life
 anxiety, 51
 Oxazepam
 ceasing use of, 195
 treatment of late-life anxiety
 with, 198
 Pachana, Nancy, 5, 7
 Palliative care settings, late-life
 anxiety in
 anxiety as symptom, 166
 caregivers and, 167
 clinical assessment of late-
 life anxiety and, 167
 exacerbation of anxiety,
 166–167
 family and, 167
 generalized anxiety disorder
 (GAD) and, 166
 overview, 165–166
 palliative care defined,
 165
 panic disorder and, 166
 pharmacological
 treatment, 167
 post-traumatic stress
 disorder (PTSD) and,
 166
 psychosocial treatment, 167
 Palmer, K., 121, 227–228
 Panic disorder
 clinical assessment of
 late-life anxiety and, 86–87
 cognitive behavioural
 therapy (CBT) and, 173
 in palliative care settings, 166
 Panic Disorder Severity
 Scale, 82
 Parker, G., 26
 Parkinson's disease, late-life
 anxiety and
 Acceptance and
 Commitment Therapy
 (ACT) and, 148
 amygdala and, 145
 anterior cingulates and, 145
 anxiety disorders not
 otherwise specified
 (ADNOS) and, 140,
 141–142
 Anxiety Status Inventory
 (ASI) and, 142
 Beck Anxiety Inventory
 (BAI) and, 142, 147
 benzodiazepines (BZDs)
 and, 146
 brain-derived neurotrophic
 factor (BDNF) and, 145
 characteristics of anxiety,
 143, 144
 clinical assessment of late-
 life anxiety and, 89,
 142–143

- Parkinson's disease (cont.)
 cognitive behavioural therapy (CBT) and, 52, 146–148, 174, 179
 cognitive functioning and, 125
 co-morbidity, 16
 deep brain stimulation (DBS) treatment, 142
 Depression, Anxiety and Stress Scale (DASS-21) and, 147
 diffusion tensor imaging (DTI) and, 145
 dopamine dysregulation syndrome (DDS) and, 142
 dopamine withdrawal syndrome (DWAS) and, 142
 functional magnetic resonance imaging (fMRI) and, 145
 future research, 149
 generalized anxiety disorder (GAD) and, 139–140
 genetic factors and, 145–146
 Geriatric Anxiety Inventory (GAI) and, 143
 group psychodrama and, 148
 Hamilton Anxiety Rating Scale (HAM-A) and, 142, 147
 Hospital Anxiety and Depression Scale (HADS) and, 142, 147
 impulse control disorders (ICDs) and, 142
 Liebowitz Social Anxiety Scale (LSAS) and, 142
 MDS-UPDRS – Anxiety Item and, 142
 mindfulness-based interventions and, 148
 movement disorder, Parkinson's disease as, 139
 Neuropsychiatric Inventory – Anxiety subscale (NPI-Anxiety) and, 142
 neurotransmitters and, 144–145
 noradrenergic locus ceruleus and, 145
 onset of anxiety, 143, 144
 overview, 6, 139, 149
- Parkinson's Disease Anxiety Scale (PAS) and, 143
 paroxetine and, 146
 Patient Education Program Parkinson's (PEPP) and, 148
 pharmacological treatment, 146
 positron emission tomography (PET) and, 145
 prevalence of anxiety, 139
 prevalence of Parkinson's disease, 139
 psychosocial treatment, 146–148
 rating scales and, 142–143
 risk factor, anxiety as, 228–229
 selective serotonin reuptake inhibitors (SSRIs) and, 146
 serotonergic raphe nucleus and, 145
 sertraline and, 146
 single-photon emission computed tomography (SPECT) and, 145
 Spielberger State Trait Anxiety Inventory (STAI) and, 142, 147
 striatal dopamine transporter (DAT) density and, 145
 subthreshold late-life anxiety, co-morbidity with, 49
 subtypes of anxiety, 139–140
 symptoms of anxiety, 140–141
 Zung Self-Rated Anxiety Scale (SAS) and, 142
- Parkinson's Disease Anxiety Scale (PAS), 143
 Paroxetine
 ceasing use of, 195
 Parkinson's disease and late-life anxiety and, 146
 Parslow, R., 22
 Passionflower, 201, 232
 Patient Education Program Parkinson's (PEPP), Parkinson's disease and late-life anxiety and, 148
 Patient-Reported Outcomes Measurement Information System (PROMIS), 84
 Pavlovian fear conditioning, 206–207
 PD Anxiety-Motor Complications Questionnaire (PDAMCQ), 228
 Pedersen, N. L., 226–227
 Penn State Worry Questionnaire (PSWQ), 84–85, 201
 Pennywort, 201, 232
 Perry, G., 123
 Perumal, Bhagvathi, 7
 PET. *See* Positron emission tomography (PET)
 Petersen, R. B., 123
 Petkus, Andrew J., 6, 111
 Pharmacological treatment of late-life anxiety. *See also specific drug*
 adverse effects, 193–194
 antidepressants (*See* Antidepressants)
 antipsychotics (*See* Antipsychotics)
 attention bias, 110–111
 ceasing use of psychotropic medication, 195
 clinical assessment of late-life anxiety prior to, 193
 clinical context of, 190
 clinical trials, lack of, 195
 cognitive behavioural therapy (CBT) versus, 201
 cognitive functioning and, 130
 cognitive impairment, in presence of, 194
 combination with cognitive behavioural therapy (CBT), 174, 201
 combination with psychosocial treatment, 174, 201
 co-morbidity and, 191
 complementary medicine, 201
 conventional psychotropic medication, 231–232
 cross-cultural issues, 72
 future research, 202, 230–231
 gamma-aminobutyric acid (GABA) system and, 189

- Geriatric Anxiety Inventory (GAI) and, 192
 Geriatric Anxiety Scale (GAS) and, 192
 Hamilton Anxiety Rating Scale (HAM-A) and, 192
 in home-based care, 164–165
 limitations of evidence, 195
 in long-term care, 190, 194–195
 measurement of treatment effect, 191–192
 novel agents, 232
 overview, 5, 6, 189, 202–000
 in palliative care settings, 167
 Parkinson's disease, late-life anxiety and, 146
 pharmacodynamic considerations, 190–191
 pharmacokinetic considerations, 190–191
 phytomedicines, 201, 232
 polypharmacy, 191
 post-traumatic stress disorder (PTSD), 176
pro re nata (as needed), 192
 psychiatric visits, 190
 psychological impact of, 192–193
 psychosocial treatment versus, 201
 rationale for drug use, 189–190
 subthreshold late-life anxiety, 51
 PhD-level providers (PLPs), 182
 Phobias
 clinical assessment of late-life anxiety and, 85
 Social Phobia and Anxiety Inventory (SPAI), 86
 Social Phobia Scale (SPS), 86
 subthreshold late-life anxiety and, 44–45
 Physiological measures, 88
 Phytomedicines, 201, 232
 Polypharmacy, 191
 Poon, C. Y., 108–109
 Positivity effect, 100
 Positron emission tomography (PET)
 anxiety and, 1
 neuroticism and, 2
 Parkinson's disease, late-life anxiety and, 145
 Post-traumatic stress disorder (PTSD)
 anxiety and, 2
 cognitive behavioural therapy (CBT) and, 176
 DSM-5 and, 23, 176
 in palliative care settings, 166
 pharmacological treatment, 176
 prevalence of, 176
 psychosocial treatment, 176–177
 in veterans, 176–177
 Prefrontal cortex
 anxiety and, 205
 attention bias and, 107, 109–110
 cognitive functioning and, 123, 124
 future research, 227
 mediation of fear learning and extinction in, 210–211
 neuromodulation of fear and anxiety circuits, 211
 Pavlovian fear conditioning and, 206
 physiology of, 208
 Pregabalin, 200, 231
 Prescott, C. A., 226–227
 Prevalence of late-life anxiety
 cross-cultural issues and, 66–67
 future research, 229–230
 Parkinson's disease and, 139
 population-based prevalence estimates, 12–13
 subthreshold late-life anxiety, 33–45
 Price, R. B., 100, 107
 Problem-solving therapy (PST), cognitive functioning and, 129–130
 Processing Efficiency Theory, 49, 120
 Protective factors
 cross-cultural issues in late-life anxiety and, 69–70
 for late-life anxiety, 14–16
 in subacute settings, 157
 Psionos, M., 66
 Psoriatic arthritis, comorbidity with subthreshold late-life anxiety, 51
 Psychiatric visits, 190
 Psychosocial treatment of late-life anxiety
 Acceptance and Commitment Therapy (ACT) (*See* Acceptance and Commitment Therapy (ACT))
 Adjusting to Chronic Conditions Using Education, Support, and Skills (ACCESS), 179–180
 attention bias, 110–111
 bachelor-level lay providers (BLPs), 182
 Calmer Life model, 180–181
 chronic illness and, 179–180
 cognitive behavioural therapy (CBT) (*See* Cognitive behavioural therapy (CBT))
 combination with pharmacological treatment, 174, 201
 community-academic partnership models, 182
 cross-cultural issues, 70–72
 dementia and, 178–179
 enhanced community care (ECC), 181, 182
 executive dysfunction and, 178
 fear of falling, 177–178
 future research, 182–183
 Geriatric Resources for Assessment and Care of Elders (GRACE) model, 175
 hoarding disorder, 177
 in home-based care, 165, 182
 Improving Mood – Promoting Access to Collaborative Treatment (IMPACT) model, 175
 Internet-delivered cognitive behavioural therapy (iCBT), 182, 234–235
 limitations of efficacy trials, 175
 mindfulness-based interventions (*See* Mindfulness-based interventions)
 modular approaches, 180
 need for new models, 175

- Psychosocial (cont.)
 novel delivery options, 181–182
 novel treatment models, 180–181
 overview, 5, 6, 173, 182–183
 in palliative care settings, 167
 Parkinson's disease, late-life anxiety and, 146–148
 pharmacological treatment versus, 201
 PhD-level providers (PLPs), 182
 post-traumatic stress disorder (PTSD), 176–177
 relaxation (*See* Relaxation)
 religion and/or spirituality (R/S), 180–181
 subthreshold late-life anxiety, 51–53
 telephone-based treatment, 181–182
 traditional efficacy trials, 173–175
 Vida Calma, 181
 Psychotropic medication. *See* Pharmacological treatment of late-life anxiety
 PTSD. *See* Post-traumatic stress disorder (PTSD)
- Quetiapine, 199, 231
- Race, late-life anxiety and, 234
 Ramos, Katherine, 6
 Rating Scale for Anxiety in Dementia (RAID), 4, 24, 25–26, 87, 230
 Rating scales for anxiety
 overview, 4
 Parkinson's disease, late-life anxiety and, 142–143
 Relaxation
 cross-cultural issues, 71
 in home-based care, 162
 subthreshold late-life anxiety and, 51–53
 Religion and/or spirituality (R/S), 180–181
 Religious explanation for mental disorders, 65
 Research Domain Criteria (RDoC), 226
 Reynolds, C. F., 12–13
 Ribeiro, O., 69, 230
- Richer, Marie-Josée, 5
 Risk factors
 anxiety as risk factor for other conditions, 227–229
 cross-cultural issues in late-life anxiety and, 69–70
 for generalized anxiety disorder (GAD), 15
 for late-life anxiety, 4, 14–16
 in subacute settings, 157
 Rivastigmine, 200
 Robinaugh, D. J., 67
 Rodrigues, R., 123
 Rodriguez, Rachel, 6
 Rumination, 45
- Sah, Pankaj, 7
 St John's wort, 201
 St. Louis University Mental Status (SLUMS) Examination, 128
 Salem witch trials, 65
 Savage, K., 232
 Schuurmans, J., 196, 201
 Selective serotonin reuptake inhibitors (SSRIs)
 overview, 196
 Parkinson's disease and late-life anxiety and, 146
 Self-reports
 clinical assessment of late-life anxiety and, 82
 problems with, 20–21
 Serotonergic raphe nucleus, Parkinson's disease and late-life anxiety and, 145
 Serotonin and noradrenaline (norepinephrine) reuptake inhibitors (SNRIs), 196
 Sertraline
 buspirone versus, 196
 cognitive behavioural therapy (CBT) versus, 196
 Hamilton Anxiety Rating Scale (HAM-A) and, 196
 Parkinson's disease and late-life anxiety and, 146
 treatment of late-life anxiety with, 196
 Sexual abuse, cognitive functioning and, 123–124
 Shead, Veronica, 6
 Short Anxiety Screening Test (SAST), 4, 24, 25
- The Sign of Four* (Conan Doyle), 79
 Single-photon emission computed tomography (SPECT), Parkinson's disease and, 145
 Skullcap, 201, 232
 Sleep, effect of subthreshold late-life anxiety on, 45
 Snow, A. L., 230
 Social anxiety disorder, clinical assessment of late-life anxiety and, 85–86
 Social Interaction Anxiety Scale (SIAS), 86
 Social Phobia and Anxiety Inventory (SPAI), 86
 Social Phobia Scale (SPS), 86
 Socioemotional selectivity theory (SST) and, 100
 Spielberger State Trait Anxiety Inventory (STAI), 86
 Parkinson's disease and late-life anxiety and, 142, 147
 Stanley, Melinda, 6
 Steiner, A. R., 111
 Stress disorders, anxiety and, 2
 Striatal dopamine transporter (DAT) density, Parkinson's disease and, 145
 Strokes, subacute settings and late-life anxiety, 157
 Structured Clinical Interview for DSM-5 Disorders (SCID), 27, 81
 Structured interview guides, 230
 Subacute settings, late-life anxiety in
 amputation and, 158
 avoidance strategies, 158
 chronic obstructive pulmonary disease (COPD) and, 158
 communication, importance of, 159
 control, limitations on, 158
 discharge and, 158
 pain management and, 158
 personal values and goals, importance of, 159
 pre- or early admission, importance of, 159
 protective factors in, 157

- risk factors in, 157
 routine, importance of, 159
 strokes and, 157
 subacute setting defined, 157
 trust, importance of, 159
 Subthreshold late-life anxiety
 alcohol consumption and, 46
 anxiety disorders not
 otherwise specified
 (ADNOS) and, 33, 51–52
 Attention Control Theory
 (ACT) and, 49
 benzodiazepines (BZDs)
 and, 51
 cardiovascular disease
 (CVD), co-morbidity
 with, 50
 chronic obstructive
 pulmonary disease
 (COPD), co-morbidity
 with, 50
 chronic pain, co-morbidity
 with, 51
 cognitive behavioural
 therapy (CBT) and, 51–53
 cognitive impairment, co-
 morbidity with, 48–49
 daily functioning, effect on,
 45–46
 dementia, co-morbidity
 with, 48–49
 depression, co-morbidity
 with, 47
 evolution over time, 44, 48
 fear of falling and, 45
 future research, 53–54
 generalized anxiety disorder
 (GAD) and, 44, 46, 48
 headaches, co-morbidity
 with, 51
 hearing impairment, co-
 morbidity with, 51
 medication and, 46
 need for mental health
 services and, 46
 osteoporosis, co-morbidity
 with, 51
 overview, 5, 33, 53–54
 Parkinson's disease and, 49
 pharmacological treatment
 of, 51
 phobias and, 44–45
 physical illness,
 co-morbidity with, 51
 prevalence of, 33–45
 psoriatic arthritis,
 co-morbidity with, 51
 psychosocial treatment of,
 51–53
 relaxation and, 51–53
 rumination and, 45
 sleep, effect on, 45
 vision impairment, co-
 morbidity with, 51
 well-being, effect on,
 45–47
 Suicide, antidepressants
 and, 196
 Supernatural explanation for
 mental disorders, 65
 Swedish Adoption/Twin Study
 of Aging, 226–227, 228
 Tales, A., 228
 Taoism, 71
 Technology, use of in clinical
 assessment of late-life
 anxiety, 88–89
 Telehealth, 234–235
 Telephone-based treatment,
 181–182
 10/66 Study, 14
 Thyroid disease, cognitive
 functioning and,
 125
 Tricyclic antidepressants
 (TCAs)
 cross-cultural issues, 72
 overview, 196
 Troeung, L., 147
 Twin studies, cognitive
 functioning and,
 122–123
 Uchino, B. N., 88
 United States Census, 163
 Valerian, 201, 232
 van Sonderen, E., 26
 Veazey, C., 147
 Venlafaxine, 197
 Veterans Health
 Administration, 176–177
 Vida Calma, 181
 Vietnam Era Twin Study of
 Aging, 122
 Vietri, J., 100
 Virtual reality (VR)
 technology, 234
 Vision impairment, co-
 morbidity with
 subthreshold late-life
 anxiety, 51
 Watson, D., 98
 Well-being, effect of
 subthreshold late-life
 anxiety on, 45–47
 Wetherell, Julie, 6, 71, 111, 178,
 201, 233
 Williams, A. M.,
 107–108
 Williams, J. M. G., 99
 World Health Organization
 (WHO), 163, 165
 Worry
 attention bias and, 107
 cognitive functioning
 and, 119
 Years of life lived with
 disability (YLDs), 3,
 11, 205
 Years of life lost due to
 premature mortality
 (YLLs), 3
 Young, W. R.,
 107–108
 Z-drugs
 benzodiazepines (BZDs)
 versus, 198
 gamma-aminobutyric acid
 (GABA) system and,
 198
 treatment of late-life anxiety
 with, 198
 Zeilmann, C. A., 72
 Zen Buddhism, 71
 Zhang, X., 15
 Zou, J. B., 235
 Zung Self-Rated Anxiety
 Scale (SAS),
 Parkinson's disease
 and late-life anxiety,
 142